en.unionpedia.org

Sugammadex, the Glossary

Sugammadex, sold under the brand name Bridion, is a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anaesthesia.^[1]

37 relations: Acetylcholine receptor, Acetylcholinesterase, Atropine, British Journal of Anaesthesia, Cholinergic, Cochrane Library, Cyclodextrin, European Medicines Agency, European Union, Food and Drug Administration, Gallamine triethiodide, General anaesthesia, Glycopyrronium bromide, Health Canada, Intravenous therapy, Malignant hyperthermia, Merck & Co., Muscarinic antagonist, Neostigmine, Neuromuscular junction, Neuromuscular monitoring, Neuromuscular-blocking drug, New Drug Application, Newhouse Research Site, Pancuronium bromide, Pseudocholinesterase deficiency, Rapid sequence induction, Rocuronium bromide, Schering-Plough, Scotland, Selective relaxant binding agents, Space-filling model, Steroid, Sugammadex, Suxamethonium chloride, Tubocurarine chloride, Vecuronium bromide.
Oligosaccharides

Acetylcholine receptor

An acetylcholine receptor (abbreviated AChR) or a cholinergic receptor is an integral membrane protein that responds to the binding of acetylcholine, a neurotransmitter.

See Sugammadex and Acetylcholine receptor

Acetylcholinesterase

Acetylcholinesterase (HGNC symbol ACHE; EC 3.1.1.7; systematic name acetylcholine acetylhydrolase), also known as AChE, AChase or acetylhydrolase, is the primary cholinesterase in the body.

See Sugammadex and Acetylcholinesterase

Atropine is a tropane alkaloid and anticholinergic medication used to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate, and to decrease saliva production during surgery.

See Sugammadex and Atropine

British Journal of Anaesthesia

The British Journal of Anaesthesia is a monthly peer-reviewed medical journal published by Elsevier on behalf of the Royal College of Anaesthetists (and its Faculty of Pain Medicine), the College of Anaesthesiologists of Ireland, and the Hong Kong College of Anaesthesiologists, for all of which it serves as their official journal.

See Sugammadex and British Journal of Anaesthesia

Cholinergic

Cholinergic agents are compounds which mimic the action of acetylcholine and/or butyrylcholine.

See Sugammadex and Cholinergic

Cochrane Library

The Cochrane Library (named after Archie Cochrane) is a collection of databases in medicine and other healthcare specialties provided by Cochrane and other organizations.

See Sugammadex and Cochrane Library

Cyclodextrin

Cyclodextrins are a family of cyclic oligosaccharides, consisting of a macrocyclic ring of glucose subunits joined by α-1,4 glycosidic bonds. Sugammadex and Cyclodextrin are oligosaccharides.

See Sugammadex and Cyclodextrin

European Medicines Agency

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products.

See Sugammadex and European Medicines Agency

European Union

The European Union (EU) is a supranational political and economic union of member states that are located primarily in Europe.

See Sugammadex and European Union

Food and Drug Administration

The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services.

See Sugammadex and Food and Drug Administration

Gallamine triethiodide

Gallamine triethiodide (Flaxedil) is a non-depolarising muscle relaxant.

See Sugammadex and Gallamine triethiodide

General anaesthesia

General anaesthesia (UK) or general anesthesia (US) is a method of medically inducing loss of consciousness that renders a patient unarousable even with painful stimuli. Sugammadex and general anaesthesia are anesthesia.

See Sugammadex and General anaesthesia

Glycopyrronium bromide

Glycopyrronium bromide is a medication of the muscarinic anticholinergic group.

See Sugammadex and Glycopyrronium bromide

Health Canada

Health Canada (HC; Santé Canada, SC)Health Canada is the applied title under the Federal Identity Program; the legal title is Department of Health.

See Sugammadex and Health Canada

Intravenous therapy

Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein.

See Sugammadex and Intravenous therapy

Malignant hyperthermia

Malignant hyperthermia (MH) is a type of severe reaction that occurs in response to particular medications used during general anesthesia, among those who are susceptible. Sugammadex and Malignant hyperthermia are anesthesia.

See Sugammadex and Malignant hyperthermia

Merck & Co.

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm.

See Sugammadex and Merck & Co.

Muscarinic antagonist

A muscarinic receptor antagonist (MRA), also called an antimuscarinic, is a type of anticholinergic agent that blocks the activity of the muscarinic acetylcholine receptor.

See Sugammadex and Muscarinic antagonist

Neostigmine

Neostigmine, sold under the brand name Bloxiverz, among others, is a medication used to treat myasthenia gravis, Ogilvie syndrome, and urinary retention without the presence of a blockage.

See Sugammadex and Neostigmine

Neuromuscular junction

A neuromuscular junction (or myoneural junction) is a chemical synapse between a motor neuron and a muscle fiber.

See Sugammadex and Neuromuscular junction

Neuromuscular monitoring

In anesthesia, neuromuscular blocking agents may be required to facilitate endotracheal intubation and provide optimal surgical conditions. Sugammadex and neuromuscular monitoring are anesthesia.

See Sugammadex and Neuromuscular monitoring

Neuromuscular-blocking drug

Neuromuscular-blocking drugs, or Neuromuscular blocking agents (NMBAs), block transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles.

See Sugammadex and Neuromuscular-blocking drug

New Drug Application

The Food and Drug Administration's (FDA) New Drug Application (NDA) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing.

See Sugammadex and New Drug Application

Newhouse Research Site

The Newhouse Research Site is a drug research facility situated east of Glasgow in central Scotland.

See Sugammadex and Newhouse Research Site

Pancuronium bromide

Pancuronium (trademarked as Pavulon) is an aminosteroid muscle relaxant with various medical uses.

See Sugammadex and Pancuronium bromide

Pseudocholinesterase deficiency

Pseudocholinesterase deficiency is an autosomal recessive inherited blood plasma enzyme abnormality in which the body's production of butyrylcholinesterase (BCHE; pseudocholinesterase aka PCE) is impaired. Sugammadex and pseudocholinesterase deficiency are anesthesia.

See Sugammadex and Pseudocholinesterase deficiency

Rapid sequence induction

In anaesthesia and advanced airway management, rapid sequence induction (RSI) – also referred to as rapid sequence intubation or as rapid sequence induction and intubation (RSII) or as crash induction – is a special process for endotracheal intubation that is used where the patient is at a high risk of pulmonary aspiration. Sugammadex and rapid sequence induction are anesthesia.

See Sugammadex and Rapid sequence induction

Rocuronium bromide

Rocuronium bromide (brand names Zemuron, Esmeron) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia to facilitate tracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation. Sugammadex and Rocuronium bromide are drugs developed by Merck & Co..

See Sugammadex and Rocuronium bromide

Schering-Plough

Schering-Plough Corporation was an American pharmaceutical company.

See Sugammadex and Schering-Plough

Scotland

Scotland (Scots: Scotland; Scottish Gaelic: Alba) is a country that is part of the United Kingdom.

See Sugammadex and Scotland

Selective relaxant binding agents

Selective relaxant binding agents (SRBAs) are a new class of drugs that selectively encapsulates and binds neuromuscular blocking agents (NMBAs). Sugammadex and selective relaxant binding agents are anesthesia.

See Sugammadex and Selective relaxant binding agents

Space-filling model

In chemistry, a space-filling model, also known as a calotte model, is a type of three-dimensional (3D) molecular model where the atoms are represented by spheres whose radii are proportional to the radii of the atoms and whose center-to-center distances are proportional to the distances between the atomic nuclei, all in the same scale.

See Sugammadex and Space-filling model

Steroid

A steroid is an organic compound with four fused rings (designated A, B, C, and D) arranged in a specific molecular configuration.

See Sugammadex and Steroid

Sugammadex

Sugammadex, sold under the brand name Bridion, is a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anaesthesia. Sugammadex and Sugammadex are anesthesia, drugs developed by Merck & Co., oligosaccharides and Thioethers.

See Sugammadex and Sugammadex

References

[1] https://en.wikipedia.org/wiki/Sugammadex

Also known as ATC code V03AB35, ATCvet code QV03AB35, Bridion, C72H112O48S8, Esmeroff, Org 25969, Org25969, Sugamadex, Sugammadex sodium.

Sugammadex, the Glossary

Table of Contents

See also

Oligosaccharides

References